SUBSCRIBE
SUBSCRIBE
News   Business

R-Tech Ueno: Basic Agreement on the Licensing of Data of Recombinant Human Serum Albumin

October 19, 2011 | 
1 min read
TOKYO--(BUSINESS WIRE)--R-Tech Ueno (JASDAQ:4573) and the Chemo-Sero-Therapeutic Research Institute (hereinafter referred to as Kaketsuken) reached basic agreement today on the licensing of data of recombinant human serum albumin as described below:
Alliances Asia
MORE ON THIS TOPIC
Illustration of cardboard box filled with office supplies, a computer keyboard, lamp, and a potted plant
Layoff Tracker
4DMT Thins Early-Stage Workforce, Focuses on Late-Stage Activities
July 3, 2025
 · 
152 min read
 · 
BioSpace Editorial Staff
Podcast
CAR T Expands, M&A Ticks Up, Two Psychedelics Read Out, and the Supreme Court Rules on PrEP
July 2, 2025
 · 
1 min read
 · 
Heather McKenzie
A contemporary artistic collage depicting a hand holding pills, passing them to another hand. The concept of medication and treatment.
Collaboration
Argenx Makes $1.5B+ Play for UNP’s Macrocyclic Peptides Aimed at ‘Undruggable’ Targets
July 1, 2025
 · 
2 min read
 · 
Tristan Manalac
Contemporary art collage, female palms in the orange circle, a bag of money. Concept of business and finance.
Mergers & acquisitions
AbbVie Plunks Down $2.1B for Capstan and Its Novel CAR T Therapies
June 30, 2025
 · 
2 min read
 · 
Dan Samorodnitsky